PharmaCyte Biotech Inc
For the period ended Jan 31, 2024. Filed Mar 18, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jan 31, 2024 · Filed Mar 18, 2024
PMCB$0.36-4.1%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Table of Contents
INDEX TO QUARTERLY REPORT ON FORM 10-Q
THREE AND NINE MONTHS ENDED JANUARY 31, 2024
| Page | ||
|---|---|---|
| PART I. | FINANCIAL INFORMATION | 3 |
| Item 1. | Condensed Consolidated Financial Statements (Unaudited) | 3 |
| Condensed Consolidated Balance Sheets as of January 31, 2024 and April 30, 2023 (Unaudited) | 3 | |
| Condensed Consolidated Statements of Operations for the Three and Nine Months Ended January 31, 2024 and 2023 (Unaudited) | 4 | |
| Condensed Consolidated Statements of Comprehensive Loss for the Three and Nine Months Ended January 31, 2024 and 2023 (Unaudited) | 5 | |
| Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders’ Equity for the Nine Months Ended January 31, 2024 and 2023 (Unaudited) | 6 | |
| Condensed Consolidated Statements of Cash Flows for the Nine Months Ended January 31, 2024 and 2023 (Unaudited) | 8 | |
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 9 | |
| Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 26 |
| Item 3. | Quantitative and Qualitative Disclosures About Market Risk | 36 |
| Item 4. | Controls and Procedures | 36 |
| PART II. | OTHER INFORMATION | 38 |
| Item 1. | Legal Proceedings | 38 |
| Item 1A. | Risk Factors | 38 |
| Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 38 |
| Item 3. | Defaults Upon Senior Securities | 39 |
| Item 4. | Mine Safety Disclosures | 39 |
| Item 5. | Other Information | 39 |
| Item 6. | Exhibits | 39 |
| Signatures | 40 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.